目的 观察唑来膦酸联合NP方案治疗非小细胞肺癌(NSCLC)骨转移的疗效.方法 收集我院2009年7月至2011年4月收治的54例NSCLC骨转移患者,随机分为两组,每组27例.治疗组接受唑来膦酸联合长春瑞滨、顺铂(NP)方案化疗,对照组予单纯NP方案化疗.结果 对照组止痛效果总有效率为37％,治疗组总有效率为81.5％(P＜0.05).对照组骨病灶疗效总有效率为14.8％,治疗组总有效率为59.3％(P＜0.05).对照组原发病灶疗效效果总有效率为14.8％,治疗组总有效率为44.5％,两组比较差异有统计学意义(P＜0.O1).两组均未见严重不良反应.结论 唑来膦酸联合NP方案化疗对NSCLC骨转移不仅有较好的止痛作用,而且可提高化疗疗效,对于骨转移及原发病灶均有改善作用,有延长患者生存期的潜在获益可能.%Objective To evaluate the therapy of zoledronie acid combined with NF chemotherapy in the treatment of treatment of non-small cell lung cancer (NSCLC) complicated with bone metastasis. Methods We retrospectively analyzed 54 cases who had NSCLC from July 2009 to April 2011. 54 cases with NSCLC with bone metastasis were randomized into two groups, each with 27 case. Patients in experiment group were treated with combination of zoledronie acid and NP chemotherapy, and patients in the control group were treated with NP chemotherapy only. Results Response rate of bone odynolysis in experiment group and the control group were 81.5% and 37%, P< 0.05. Response rate of bone metastases in experiment group and the control group were 59.3% and 14.8%, P < 0.05. For the primary lesions, the effective rate in experiment group and the control group were 44.5 and 14.8%, P0.01. Conclusion Zoledronie acid is safe, well tolerated and very effective in treatment of NSCLC with bone metastasis.
展开▼
